Tenax Therapeutics

• Tenax Therapeutics has secured a $25 million private placement from RTW Investments to fund ongoing and planned Phase 3 clinical trials for novel cardiopulmonary therapies. • The financing includes 378,346 shares of common stock and pre-funded warrants for 3,760,726 shares, with Leerink Partners leading the placement alongside Guggenheim Securities and William Blair. • The strategic investment will strengthen Tenax's position in developing innovative cardiopulmonary treatments, with proceeds directed towards clinical advancement and general corporate operations.

Tenax Therapeutics receives FDA approval to expand its ongoing LEVEL study to 230 patients, increasing statistical power to over 95% for their oral levosimendan (TNX-103) trial in PH-HFpEF treatment.

• Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103). • Ms. Andor brings over 20 years of experience in clinical operations, including NDA submissions and approvals, to accelerate the Phase 3 LEVEL study. • Her expertise will be crucial as Tenax Therapeutics advances oral levosimendan for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). • The appointment signifies Tenax's commitment to strengthening its clinical development capabilities as it prepares for potential global regulatory filings.

Tenax Therapeutics is developing levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a condition affecting over 2 million U.S. patients.